



## Urinary Incontinence in Clinical Practice: What Every Clinician Should Know

Lisa Hickman, MD, FACOG, FACS  
 Division of Urogynecology & Reconstructive Pelvic Surgery  
 Department of Obstetrics & Gynecology  
 The Ohio State University Wexner Medical Center

MedNet21  
 Center for Continuing Medical Education

THE OHIO STATE UNIVERSITY  
 WEXNER MEDICAL CENTER

### Objectives

- To review anatomy of the pelvic floor as it relates to the pathophysiology of urinary incontinence
- To understand the office evaluation of patients with urinary incontinence
- To appreciate the management options for urinary incontinence

### Anatomy of Continence


- SNS- STORAGE of urine by relaxing detrusor, contracting the muscles in urethra bladder neck
- Somatic NS-innervates the external urethral sphincter and pelvic floor muscles- relaxation of these muscles is the first step in micturition
- PSNS- PEEING detrusor contraction, relaxation of smooth muscle of the urethra to facilitate voiding

### Anatomy of Continence

- Increases in intra-abdominal pressure exerts force on pelvic organs
- Pressure is transmitted equally to the bladder and urethra
- Urethral pressure remains greater than bladder pressure
- This relationship changes with weak urethral support

## Anatomy of Continence

- At rest, urethral resistance is generated by the interaction of:
  - Urethral smooth muscle
  - Urethral wall elasticity and vascularity
  - Periurethral striated muscle
- Each contributes ~1/3 of overall intraurethral pressure



Urogynecology & Reconstructive Pelvic Surgery 5th Ed 2021 Chpt 1, Fig 1.7

## So why should you care about UI?

- Impacts ~60% of adult women
- Incidence increases with increasing age
- Significant impacts on:
  - Quality of life
  - Sexual dysfunction
  - Medical morbidities
  - Increased mortality
  - Increased caregiver burden

Berete et al BMC Geriatr 2022

## Definitions

### Urinary incontinence: Involuntary leakage of urine

- Most common causes: Stress (cough, laugh, sneeze) and urge (Gotta go- detrusor over activity)

### Overactive bladder: Syndrome of urinary frequency (>7 voids/day) and sensory urgency $\pm$ incontinence ( $\geq 3$ episodes/day considered severe)

- Neurogenic bladder: Neurologic etiology leading to detrusor overactivity (or hypocontractile bladder)- e.g. stroke, Parkinsons, Multiple Sclerosis, etc

## Definitions

### Prevalence:

- 25% of young women
- 44-57% of middle-aged and post-menopausal women
- 75% of older women
  - Accounts for 6% of nursing home admissions

### Annual healthcare cost in U.S.

- \$19.5 Billion

Kinchen et al. J Womens Health. 2007; Morrison et al. Value Health. 2008.

## Types of Urinary Incontinence

- Stress urinary incontinence (SUI)
- Urgency urinary incontinence (UUI)
- Mixed urinary incontinence (SUI + UUI)
- Occult SUI (only occurs when prolapse reduced)
- Functional urinary incontinence (cognitive, mobility)
- Overflow urinary incontinence (2/2 chronic retention)
- Extra-urethral urinary incontinence (fistula!)
- Nocturnal enuresis (bedwetting)
- Insensible urinary incontinence (IDK)

## Differential Diagnosis

- Contributory Etiology**
- Filling and storage disorders
    - Urodynamic stress incontinence
    - Detrusor overactivity (dyspathic)
    - Detrusor overactivity (neurogenic)
    - Mixed types
  - Fistula
    - Vesical
    - Urethral
    - Urethral
  - Infectious
    - Urinary tract infection
    - Vaginitis
  - Congenital
    - Ectopic ureter
    - Epispadias
- Noncontributory Etiology**
- Functional
    - Neurologic
    - Cognitive
    - Psychological
    - Physical impairment
  - Environmental
  - Pharmacologic
  - Metabolic

### Mnemonic: DIAPPERS

- Delirium
- Urinary tract infection/Urethritis
- Atrophic vaginitis
- Pharmacologic (Drug SE)
- Psychological
- Pregnancy
- Excess urine production
- Restricted mobility
- Stool impaction

ACOG Practice Bulletin #155, 2015

## Office Evaluation of UI

### History:

- Incontinence symptoms
- Bladder storage
- Emptying
- Medical Hx
  - Neurologic issues
- Surgical Hx
- Ob Hx
- Medications
- Fluids consumed

Table 9.1 Medications that Can Affect Lower Urinary Tract Functions

Type of Medication	Lower Urinary Tract Effects
Diuretics	Polyuria, frequency, urgency
Caffeine	Frequency, urgency
Alcohol	Sedation, impaired mobility, diuresis
Narcotic analgesics	Urinary retention, fecal impaction, sedation, delirium
Anticholinergic agents	Urinary retention, voiding difficulty
Antihistamines	Anticholinergic actions, sedation
Psychotropic agents	Anticholinergic actions, sedation
Antidepressants	Anticholinergic actions, sedation
Antipsychotics	Anticholinergic actions, sedation
Sedatives/hypnotics	Sedation, muscle relaxation, confusion
Alpha-adrenergic blockers	Stress incontinence
Alpha-adrenergic agonists	Urinary retention, voiding difficulty
Calcium-channel blockers	Urinary retention, voiding difficulty

Urogynecology &amp; Reconstructive Pelvic Surgery 5th Ed. 2021, Chpt 9, Table 9.1

## Office Evaluation of UI

### Physical Exam:

- Pelvic exam
  - Inspection of vulva
  - Cough Stress Test- check for leak, urethral hypermobility (>30 degree deviation from horizontal)
  - Speculum exam +/- Pelvic Organ Prolapse Quantification (POP-Q) exam
  - Bimanual



# OAB/UII

## Epidemiology of OAB

- **NOBLE study of adults >18yo**
  - 17% reported OAB symptoms
  - Women more likely to have “OAB-wet”
- **EpiLUTS study of adults >40 years**
  - 43% of women report OAB symptoms at least “sometimes”
- **Prevalence/severity increase with age, but other measures of frailty may be important**

Stewart WF et al World J Urol 2003; Milsom I et al, Urology 2012; Suskin AM et al Urology

## Other OAB considerations

**Evaluations:**

- Mini-mental state exam
- Ability to perform ADLs
- Ambulation: Do they use an aid? Are they a fall risk?
- LE edema/diuretic use
- Diabetes: Glycemic control/medications
- Overall frailty

## Diagnosis & Treatment Algorithm

Diagnosis & Treatment Algorithm: AUA/SUFU Guideline on Non-Neurogenic Overactive Bladder in Adults

History and Physical/Urinalysis: Symptoms of OAB (i.e. urge incontinence).  
 Patient Education: Educate about urinary tract function and benefits/risks of treatments; agree on treatment goals. Focus on bladder control, lifestyle changes, and treatment goals.  
 Behavioral Treatments: OAB can be controlled with pharmacologic management. Treatment goals met? If not, consider alternative treatments. Patient education, bladder diary, and/or pelvic floor therapy. If all interventions fail, consider referral to urology for further management.  
 Pharmacologic Management: Consider drug modification or alternate medication if initial treatment is ineffective. Consider anticholinergics, beta-3 agonists, and/or combination therapy. Consider referral to urology for further management if all interventions fail.  
 Reassess and/or Refer: Consider urine culture, post-void residual, bladder diary, symptom exacerbation.  
 Treatment Goals Met: Consider if curative selected and thoroughly counseled patients with moderate to severe symptoms. Consider urine culture, post void residual bladder size, and/or symptom exacerbation. Not OAB or complicated OAB treat as such.  
 Consider if curative selected and thoroughly counseled patients with moderate to severe symptoms: Consider urine culture, post void residual bladder size, and/or symptom exacerbation.

\*Consider urine culture, post void residual bladder size, and/or symptom exacerbation.  
 \*Consider urine culture, post void residual bladder size, and/or symptom exacerbation.  
 \*Consider urine culture, post void residual bladder size, and/or symptom exacerbation.  
 \*Consider urine culture, post void residual bladder size, and/or symptom exacerbation.

AUA/SUFU Guideline 2024

## Behavioral Treatments

- **Should be first line management (moderate-quality evidence)**
- **These include:**
  - Drinking to thirst (<math>\leq 68\text{oz}</math> fluid/day)
  - Avoiding bladder irritants (coffee, alcohol)
  - Urge suppression techniques (distraction, quick flicks, belly breathing)
  - Cutting back fluids 2-3 hours before bed (for nocturia)
  - Bladder training



## Behavioral Treatments

- **Can be as effective or more effective than anti-muscarinics for:**
  - Reducing UI episodes
  - Improving frequency/urgency, nocturia
  - Improving QOL
- **25% reduction in fluid intake can improve frequency/urgency**
- **Bladder training/PFME can improve symptoms by 50-80%**

Dugan et al PM&R 2013

## Behavioral Treatments

### Other options to consider:

- Ensure using CPAP
- Lower extremity elevation in evenings
- Compression stockings
- Timing of diuretics (or adding diuretic in PM for nocturia)
- Bedside commode
- Timed voiding
- Purewick?

## Pharmacologic Management

### Two classes:

- **Anti-muscarinics (Anti-cholinergics)**
  - Non-selective, receptors throughout body
  - M2 most prevalent (80%), but M3 most active in the bladder (20-30%)
  - Anti-spasmodic effect on detrusor muscle → increases capacity and delays desire to void
- **Beta-3-Adrenergics**
  - Act on Beta-3-receptors releasing NE
  - Increases urethral outlet resistance and promotes bladder muscle relaxation



## Antimuscarinics

- **Oxybutynin (Ditropan): Tertiary amine with additional effects of myotrophic relaxation and local anesthesia (M3:M1 selective)**
  - A/w most cognitive effects (highest somnolence)
  - Transdermal has lowest rate of dry mouth (also OTC!)
- **Tolterodine (Detrol): Tertiary amine with M3 affinity**
- **Tropium (Sanctura): Quaternary amine (limited BBB penetration)**
  - Lowest rates of dry mouth

## Antimuscarinics

- **Solifenacin (Vesicare): M3:M2 selective**
- **Darifenacin (Enablex): Most highly M3 selective**
- **Festoterodine (Toviaz): Converted to 5-HydroxyMethylTolterodine**

No one anticholinergic has been shown to be superior to others; just different side effect profiles

## Antimuscarinics

### Side effects:

- **Dry mouth 10-60% (MCC for discontinuation)**
- **Constipation 3-10%**
- **Dry eyes**
- **Can also cause dyspepsia due to slowed emptying**
  - Careful with KCl use can increase risk of gastritis and higher absorption

## Antimuscarinics

- **Antimuscarinics reduce urgency leaks by ~2 and frequency episodes by ~2**
  - 40% improvement is typically seen
  - Chance of becoming dry with medications ~10%
- **ER formulations have less dry mouth than IR (oxybutynin, tropium, and tolterodine)**
- **<½ will ever refill anticholinergic meds**
- **Bladder botox is more cost-effective than anticholinergics**

## Anticholinergic medications

- 30-50% of older adults take at least 1 AC medication
- Known to have cognitive adverse effects including confusion and memory loss
- Decline in cognitive function and mild cognitive impairment a/w increased risk of dementia

## Anticholinergic medications

Many medications have anticholinergic effects:

- Antihistamines
- Anti-Parkinson medications
- Opioids
- Inhaled bronchodilators
- Anti-emetics
- Muscle relaxants
- Psychotropic drugs
- And more! [UpToDate Anticholinergic medications](#)

## Concern with anticholinergics

- JAMA, n=284,000 patients  $\geq 55$  years
  - ~1500 practices in England (database study)
  - No Parkinsons or dementia during enrollment
  - Cases: diagnosed during dementia during follow-up
  - Controls: Matched 5:1 for age and sex
  - Exposure: Cumulative AC drug exposure prescribed in 1-11 years prior to diagnosis
  - AOR for bladder antimuscarinics= 1.65 (CI 1.56-1.75)
- American Urogynecologic Society recommends avoidance of these medications in individuals  $\geq 70$  years old

Coupland et al JAMA 2019; AUGS Clinical Consensus Statement 2020

## Beta-3 Adrenergics

**Mirabegron (Myrbetriq): Dosed 25mg or 50mg daily**

- Side effects:
  - HTN (uncontrolled HTN is CI for prescribing)
  - Nasopharyngitis
  - UTI (due to some level of retention)
  - Headache, dry mouth
  - Has vasoconstrictive effects
- Should not be prescribed for women on tamoxifen or beta-blockers d/t CYP effects

## Beta-3 Adrenergics

### Vibegron (Gemtesa): Dosed 75mg daily

- **Differences from mirabegron:**
  - No warning for HTN
  - Does not have CYP effects
  - No generic
- **Similarities: Has vasoconstrictive effects**
  - Nasopharyngitis
  - UTI (due to some level of retention)
  - Headache, dry mouth

## Getting meds covered...

Good idea to advise your patients that we may not get an affordable med on the first prescription


- All antimuscarinics are generic
  - Can use GoodRx or CostPlusDrugs
- Mirabegron is generic but not currently covered by these plans
  - Some Medicare plans cover brand (Myrbetriq- need to DAW)
- Vibegron is not yet generic
  - Can use coupon program through manufacturer if privately insured

## Procedural options

- Posterior tibial nerve stimulation (PTNS)
- Implantable Tibial Neuromodulation
- Sacro neuromodulation (SNM)
- Intradetrusor botox

## Posterior Tibial Nerve Stimulation


- Stimulates S2-4 via tibial n
- Qwk x12 weeks, then maintenance Q3-6w
  - No objective difference between Tolterodine but improved patient global assessment; other studies say better than meds
  - Over 50% improvement; but not as good as SNM/Botox
  - PTNS vs Tolterodine: Subjectively PTNS better; Objectively no difference; PTNS better than sham



American Urologic Society VoicesForPFD.org

## Implantable Tibial Neuromodulation

- FDA approved in Sept 2025!!
- Approximately ½ length of stick of gum
- 15-year battery lifespan
- Recharging takes 30 minutes
- MRI compatible
- Implanted in the office under local



Images courtesy of Medtronic

## Sacroneuromodulation

- Lead placed through S3 foramen
- Blocks abnormal afferent impulses

• FDA approved for OAB, UII, idiopathic incomplete bladder emptying and FI!

• Great for combo UII/FI patients

- Can do PINE (peripheral nerve eval) which is like a stage 1, done in the office, with a temporary lead → proceed with combo 1 & 2

page 2

uring trial



American Urogynecologic Society VoicesForPFDD.org

## Sacroneuromodulation

- 80% of patients achieved continence or >50% improvement in their main incontinence sx after SNS
- Revision 3-16%; infection <5%
- Batteries last 10-15 years, now MRI compatible
- Smaller rechargeable option available as well

## Intradetrusor Botox

- Botox prevents release of Ach from the nerve terminals (SNAP/SNARE complex) by cleaving a protein on the receptor in the nerve ending; decrease sx; increase capacity
- Redose Q5-10mo
- 6% cath rate with 100u
- UTI's: 20-40%
- 2/3 are continent; 60-90% have positive clinical response



Amundsen et al JAMA 2016; American Urogynecologic Society VoicesForPFDD.org

## Intradetrusor Botox

- 25% will refuse second injection
- Botox contraindicated in myasthenia gravis and ALS (peripheral motor neuropathy)
- Botox at 2 yrs more cost effective than SNM but at 5y SNM was more cost effective
- ABC trial (Anticholinergic vs Botox)- mean reduction of UI was ~3 (started at 5 leaks/day)
  - More patients were dry

Visco et al NEJM 2012

## SUI

## SUI Management

### Non-surgical

- Behavioral/lifestyle modifications
  - Weight loss
  - Fluid management
  - Bladder training
- PFME/PFPT
- Bladder neck support
  - Incontinence pessary, Vaginal insert
  - Vaginal E2

### Surgical

- Mid-urethral slings
- Pubovaginal sling
- Retropubic colposuspension
- Urethral bulking injection\*

## Weight loss

- RCT comparing a 6-month weight loss program vs structured education program in overweight and obese women
- Moderate amount of weight loss (8% of baseline weight) showed a reduction in weekly incontinence episodes:
  - 47% in overweight patients
  - 28% in obese patients
- Obesity also diminishes efficacy of mid-urethral slings (BMI >40)

Subak et al. N Engl J Med 2009

## Behavioral Modifications

### Fluid management

- Recommend reduction in excessive fluid intake
- No more than 68oz per day

### Bladder training

- Timed voiding
- Aims to increase the time interval between voiding by use of a mandatory self-adjusted schedule
- Effective in patients with SUI or UUI

Wallace et al. Cochrane Review. 2004

## Pelvic Floor Muscle Exercises/PT

- Aims at strengthening the urethral sphincter and levator ani muscles
- Alone or augmented with bladder training, biofeedback, or electrical stimulation
- Optimal regimen has yet to be determined
  - 10-15 contractions, 2-10 seconds, 3x/day
  - Efficacy demonstrated with 30-50 daily contractions
- E-stim alone has never been shown to be superior than well done PFME= no need to buy \$\$ devices

## Pessaries

### Ring with knob, Incontinence dish +/- support

- Option for patients looking for more immediate symptom control than what is provided by behavioral-PT
- May improve symptoms, but objective evidence regarding effectiveness has not been reported




Urogynecology & Reconstructive Pelvic Surgery, 5<sup>th</sup> Ed. 2021, Chpt 14 Fig 14.6

## Vaginal Inserts

### Poise impressa inserts

- Similar to tampon, disposable
- Fitting kit
- Can be purchased OTC in the incontinence product aisle
- Can be good option for younger women who prefer not to use a pessary
- Costly (vs pessary), better for PRN use



Urogynecology & Reconstructive Pelvic Surgery 5<sup>th</sup> Ed. 2021, Chpt 14 Fig 14.5

## Estrogen

### Systemic HRT

- Systemic estrogen +/- progesterone does not appear to be effective
- Women who are continent have a higher incidence of developing incontinence on estrogen
- Women who were incontinent had a higher incidence of worsening incontinence

Hendrix et al. JAMA 2005; Cody et al. Cochrane Review. 2012

## Estrogen

### Vaginal estrogen

- Increases the concentration of alpha- adrenergic receptors in the urethra and bladder improving vascularity of the periurethral increases thickness of the urethral epithelium
- Locally administered may be beneficial (and likely won't hurt!)

Hendrix et al. JAMA 2005; Cody et al. Cochrane Review. 2012

## Pharmacotherapy?

- Currently no FDA approved medication for SUI
- Duloxetine
  - Serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor → promotes urine storage
  - Mixed reports on efficacy
  - Not recommended

## Surgery

- Surgery is indicated for appropriately counseled women with SUI who have insufficient treatment control after conservative treatment
- Surgery is an appropriate 1<sup>st</sup> line treatment in appropriately counseled women who decline conservative treatment

Labrie et al. N Engl J Med. 2013

## Mid-urethral Slings

- Mid-urethral sling: most common primary surgical treatment for SUI in women
- Types:
  - Retropubic
  - Transobturator
  - Single incision or Mini-sling



American Urogynecologic Society VoicesForPFDD.org


## Mid-urethral Slings

- Retropubic MUS and TOT MUS are comparable in terms of efficacy and patient satisfaction
- Richter et al. TOMUS trial, N=597
  - Multicenter, randomized controlled equivalence trial comparing TVT and TOT
  - Similar rates subjective and objective success (~80% significantly improved or dry)
  - Differences in complications

Richter et al. N Engl J Med. 2010

## Urethral Bulking

- Injection of bulking agent into the periurethral tissue of bladder neck/proximal urethra
- Goal: Increase urethral resistance
- Agent: Bulkamid product, 97% water/2.5% polyacrylamide gel
- Approach: Peri- or transurethral
- 5-minute procedure under sedation
- 60-70% dry or significantly improved
- 85% still satisfied with result at 1 year
- At 7 years, success in over 2/3\*




American Urogynecologic Society VoicesForPFDD.org

## Urethral Bulking

- Appropriate for:
  - Women who wish to avoid mesh or surgical downtime
  - Those with recurrent or persistent SUI after surgery
  - Women with SUI without urethral mobility (ISD)
  - Older women with comorbidities
- Shortcomings
  - Recurrent SUI
  - Need for repeat injections
  - Less effective than other procedures


## Other Surgical Procedures

- **Burch colposuspension**
  - Largely replaced by mid-urethral sling
- **Autologous fascial bladder neck sling**
  - Reserved for:
    - Severe SUI with a nonmobile, fixed urethra
    - Concomitant urethral reconstructive procedures
    - Complications from previously placed mesh



Urogynecology & Reconstructive Pelvic Surgery 5<sup>th</sup> Ed. 2021, Chpt 15 Fig 15.2 (top), Chpt 16 Fig 16.6 (bottom)

## In Summary: Office Evaluation



## In Summary: Office Management

- Behavioral and diet/lifestyle modifications can be a helpful starting place for any patient with UI
- Can consider PFME/pelvic floor PT referral which has demonstrated efficacy for both SUI and UUI/OAB
- For OAB/UUI, medication management is often where I start (in addition to recommending behavioral modifications) and beta-3's are better tolerated, but not more effective than anticholinergics
- For SUI, you can recommend over-the-counter vaginal inserts
- If you aren't sure- feel free to refer to urogynecology!

## Conclusions

- Majority of UI work-up can be performed during a routine office visit
- A variety of providers play an important role in the diagnosis and management of UI- if you ask, patients will often tell
- You can give a general overview of what your patients can expect at a visit with a urogynecologist or start basic workup/treatment for OAB/UUI and SUI for patients interested in nonsurgical management

## Conclusions

- Most UI can be managed conservatively
- When this fails- consider referral to Urogyn for evaluation of surgical management of SUI or third line therapy for UUI
  - Consider procedural therapies for patients who fail/cannot tolerate medication management for UUI
- Urogyn's can also help with a multitude other PFD's including surgical management of pelvic organ prolapse, fecal incontinence, vulvovaginal pain disorders, fistula, UTIs, IC/BPS, and many more!